ARTICLE | Finance
Modis’ mitochondrial modification
How early clinical data enabled Modis to raise $30M series A for mitochondrial program
October 5, 2018 4:04 PM UTC
Compassionate use data from its lead program enabled rare genetic disease company Modis Therapeutics Inc. to attract $30 million in series A funding co-led by F-Prime Capital Partners and OrbiMed Advisors.
Founding investor Aceras Life Sciences and new investor Osage University Partners also joined the round, which closed on Oct. 1...
BCIQ Company Profiles